Inhibitors of growth factor receptor EGFR and Raf kinase suppress the activation of downstream kinases (i.e., MEK and ERK) in this signaling pathway, thereby offering significant benefits for many cancer patients [4-8]. The gene discussed is MAP2K7; the disease is cancer.